Raphael Pharmaceutical Inc.

Equities

RAPH

US27785B2088

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 07:00:19 25/06/2024 pm IST			5-day change	1st Jan Change
1.65 ^USD	+120.00%		+0.61%	+65.00%

15/05	Raphael Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02/05	Raphael Pharmaceutical Inc. Begins Proof-Of-Concept Clinical Trial in the United States	CI

RAPHAEL PHARMACEUTICAL INC. : Other Events (form 8-K)

March 29, 2023 at 01:33 am IST

Item 8.01. Other Events

On March 27, 2023, the Israeli Ministry of Health approved Raphael Pharmaceutical Inc.'s application to commence a Phase IIa clinical trial in COVID-19 patients under the protocol that was approved by the Helsinki Committee at Rambam Hospital on December 8, 2022. The clinical trial will involve a cannabis-based drug aimed at mitigating deterioration in COVID-19 patients.

Latest news about Raphael Pharmaceutical Inc.

Raphael Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
Raphael Pharmaceutical Inc. Begins Proof-Of-Concept Clinical Trial in the United States	03/05	CI
Raphael Pharmaceutical Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
Raphael Pharmaceutical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
Raphael Pharmaceutical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10	CI
Raphael Pharmaceutical Inc. Contemplates Bankruptcy	26/23/26	CI
Raphael Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
Raphael Pharmaceutical Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	24/23/24	CI
Raphael Pharmaceutical Inc. Auditor Raises 'Going Concern' Doubt	24/23/24	CI
Raphael Pharmaceutical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/22/14	CI

Chart Raphael Pharmaceutical Inc.

Duration

Period

More charts

Company Profile

Raphael Pharmaceutical Inc. is a pharmaceutical drug research and development company. The Company is focused on the discovery and clinical development of life-improving drug therapies based on cannabinoids, including cannabidiol (CBD) oil. The Company is in pre-clinical development stage for its lead product candidate, rheumatoid arthritis (RA), for the treatment of RA. In addition, the Company is also developing a pharmaceutical drug product for the treatment of hyperinflammatory syndrome inflammation related to COVID-19. The Companyâs discovery platform focuses the use of CBD oil, one of the cannabinoids in cannabis plants, as the active pharmaceutical ingredient (API), for its RA product candidate and COVID-19 product candidate.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
RAPHAEL PHARMACEUTICAL INC.	+65.00%	30.86M
MODERNA, INC.	+21.85%	46.93B
LONZA GROUP AG	+37.63%	39.08B
IQVIA HOLDINGS INC.	-8.05%	38.48B
ALNYLAM PHARMACEUTICALS, INC.	+29.04%	31.01B
CELLTRION, INC.	-13.75%	26.14B
ICON PUBLIC LIMITED COMPANY	+10.65%	25.88B
MEDPACE HOLDINGS, INC.	+38.43%	12.53B
BIO-TECHNE CORPORATION	-6.92%	11.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-12.29%	10.65B

Other Biotechnology & Medical Research